Skip to main content
OpenTrials
Completed

NCT Number: NCT05508503

A Study on a Blood-based Dual-target Test for CRC Detection

To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Usually, colorectal cancers (CRCs) diagnosed in their early stages are curable, especially precancerous lesions (adenomas, polyps) that can be removed during a colonoscopy.However, due to low patient compliance and limited resources, colonoscopy is not feasible for screening the average-risk population. gFOBT/FIT are limited by their low sensitivity and high false-positive rate. Compared to colonoscopy and stool DNA tests, blood-based methylation tests showed greater patient compliance and convenience. Hypermethylated NTMT1 and MAP3K14-AS1 were found in multiple cohorts of CRC samples in our previous study. In this study, we aimed to evaluate the effectiveness and accuracy of the ctDNA dual-target(NTMT1 and MAP3K14-AS1) test kit in 5 tertiary hospitals around china for the detection of colorectal cancer and advanced adenomas. Fecal immunochemical test (FIT) will also privided to participants in the study. Sanger sequencing would be performed to evalute the accuracy of the dual-target methylation detection test kit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion Criteria for CRC group(≥30%) 1)Patients with colorectal cancer 2)Follow-up sample subjects: Subjects who underwent resection of colorectal cancer lesions.
  • Inclusion Criteria for Control group(≤70%) Health volunteer, or subject with other diseases or physiological conditions other than colorectal cancer, including but not limited to gastritis, gastric cancer, esophagitis, rheumatoid arthritis, prostate cancer, microbes (inflammation patients), gastrointestinal bleeding, drugs (typical digestive tract medication) Population), neuroendocrine cancer, squamous cell carcinoma (squamous squamous cell carcinoma, esophageal squamous cell carcinoma);

Exclusion criteria

  • Patients who had undergone radical resection of bowel cancer (except for postoperative follow-up) and those who had received anti-tumor therapy such as radiotherapy/chemotherapy;
  • Colorectal cancer or colorectal adenoma with other malignancies;
  • Postoperative follow-up patients of colorectal cance with distant metastasis;
  • The sample size collected did not meet the detection requirements;
  • Other patients who are considered unsuitable for this study (such as pregnancy, high blood pressure, heart disease, etc., who are not suitable for colonoscopy due to physical condition).

Treatment and study plan

Test of methylated NTMT1 and MAP3K14-AS1

Diagnostic Test

A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.

FIT

Diagnostic Test

Fecal immunochemical test(optional)

Primary outcomes

  1. Sensitivity

    Time frame: Through study completion, an average of 1 year.

    Sensitivity (for CRC and\\or advanced precancerous neoplasm) of this blood-based methylation dual-target test. A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. Other clinically acceptable diagnostic criteria for non-intestinal diseases.

  2. Specificity

    Time frame: Through study completion, an average of 1 year.

    Specificity (for CRC and\\or advanced precancerous neoplasm) of this blood-based methylation dual-target test. A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. Other clinically acceptable diagnostic criteria for non-intestinal diseases.

  3. Accuracy

    Time frame: Through study completion, an average of 1 year.

    Accuracy of the kit for methylation detection. Validation of the methylation status of MTNT1 and MAP3K14-AS1 by Sanger sequencing.

Secondary outcomes

  1. Combined sensitivity

    Time frame: Through study completion, an average of 1 year.

    Sensitivity when combined the blood-based methylation dual-target test with FIT

  2. Combined specificity

    Time frame: Through study completion, an average of 1 year.

    Specificity when combined the blood-based methylation dual-target test with FIT

Sponsors and collaborators

Lead sponsor

Changhai Hospital

Other

Collaborators

  • Henan Provincial People's Hospital
  • Qilu Hospital of Shandong University
  • The Second Hospital of Hebei Medical University
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Registry information

Official study title

Validation of a ctDNA Methylation-based Dual-target Test for the Detection of Colorectal Cancer: a Multicenter Clinical Study

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 19, 2022
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.